The awarded money will be used by OPKO’s wholly-owned Mexican subsidiary Exakta-OPKO to enhance the development of research projects in ophthalmology, infectious disease and oncology.
OPKO chairman and CEO Phillip Frost said they believe that these grants will help facilitate high caliber research projects and the development of important therapeutic and diagnostic products for Mexico and Latin America.